At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Observer Blind, Controlled, Multicenter Study to Assess Immunogenicity and Antibody Persistence Following Vaccination With GSK's Candidate Combined Measles, Mumps, and Rubella Vaccine (MMR) Versus M-M-R® II as a First Dose, Both Administered Subcutaneously at 12-15 Months of Age, Concomitantly With Hepatitis A Vaccine (HAV), Varicella Vaccine (VV) and Pneumococcal Conjugate Vaccine (PCV) But at Separate Sites.
In Brief
A Phase 2 clinical trial evaluating GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), and 3 other interventions for Rubella and 3 related conditions. Completed, enrolled 1,259 participants across 48 sites in 2 countries.
Detailed Summary
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. Additionally, antibody persistence will be assessed one and two years after administration of MMR vaccine. The Protocol Posting has been updated following Protocol amendment 1 and 2, Oct 2009.
Study Details
Timeline
Interventions
Subcutaneous injection, one dose
Subcutaneous injection, one dose
Subcutaneous injection, one dose
Intramuscular injection, one dose
Intramuscular injection, one dose